Journal Article

Monitoring of efficacy, tolerability and safety of artemether–lumefantrine and artesunate–amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Lambaréné, Gabon: an open-label clinical trial

Velavan, Thirumalaisamy P., Lotola-Mougueni, Fabrice, Kreidenweiss, Andrea, Edoa, Jean R., Agnandji, Selidji T., Honkpehedji, Yabo J., Mombo-Ngoma, Ghyslain, Koehne, Erik, Lalremruata, Albert, Adegbite, Bayode R., Kremsner, Peter G., Zinsou, Frejus J., Nguyen, The T., Obone Atome, Fridia A., Mbong-Ngwese, Mirabeau, Lell, Bertrand, Mordmüller, Benjamin, Ramharter, Michael, Adegnika, Ayola A., Safiou, Abdou R., Dejon-Agobe, Jean C., Kun, Jutta

2019

Overview

Background Malaria remains a major public health problem, affecting mainly low-and middle-income countries. The management of this parasitic disease is challenged by ever increasing drug resistance. This study, investigated the therapeutic efficacy, tolerability and safety of artemether–lumefantrine (AL) and artesunate–amodiaquine (AS–AQ), used as first-line drugs to treat uncomplicated malaria in Lambaréné, Gabon. Methods A non-randomized clinical trial was conducted between October 2017 and March 2018 to assess safety, clinical and parasitological efficacy of fixed-doses of AL and AS–AQ administered to treat uncomplicated Plasmodium falciparum malaria in children aged from 6 months to 12 years. After 50 children were treated with AL, another 50 children received ASAQ. The 2009 World Health Organization protocol for monitoring of the efficacy of anti‑malarial drugs was followed. Molecular markers msp1 and msp2 were used to differentiate recrudescence and reinfection. For the investigation of artemisinin resistant markers, gene mutations in P fk 13 were screened. Results Per-protocol analysis on day 28 showed a PCR corrected cure rate of 97% (95% CI 86–100) and 95% (95% CI 84–99) for AL and AS–AQ, respectively. The most frequent adverse event in both groups was asthenia. No mutations in the kelch - 13 gene associated with artemisinin resistance were identified. All participants had completed microscopic parasite clearance by day 3 post-treatment. Conclusion This study showed that AL and AS–AQ remain efficacious, well-tolerated, and are safe to treat uncomplicated malaria in children from Lambaréné. However, a regular monitoring of efficacy and a study of molecular markers of drug resistance to artemisinin in field isolates is essential. Trial registration ANZCTR, ACTRN12616001600437 . Registered 18 November, http://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616001600437p&isBasic=True

• Publisher: BioMed Central,Springer Nature B.V,BMC
• Subject: Amodiaquine / Amodiaquine - therapeutic use / Antimalarials - therapeutic use / Artemether / Artemether, Lumefantrine Drug Combination - therapeutic use / Artemether–lumefantrine / Artemisinin / Artemisinins - therapeutic use / Artesunate / Artesunate–amodiaquine / Asexuality / Asthenia / Biomedical and Life Sciences / Biomedicine / Child / Child, Preschool / Children / Clinical trials / Deoxyribonucleic acid / DNA / Drug Combinations / Drug dosages / Drug Monitoring - statistics & numerical data / Drug resistance / Drugs / Efficacy / Entomology / Female / Gabon / Haplotypes / Hemoglobin / Human diseases / Humans / Infant / Infectious Diseases / Laboratories / Malaria / Malaria, Falciparum - drug therapy / Male / Microbiology / Mutation / Nucleotide sequence / Organizations / Parasites / Parasitic diseases / Parasitology / Parasitoses / PCR / Plasmodium falciparum / Plasmodium falciparum - drug effects / Plasmodium falciparum - isolation & purification / Polymerase chain reaction / Protozoan Proteins - genetics / Public Health / Safety / Tolerability / Tropical Medicine / Vector-borne diseases